Skip to content
etf.net

Launched · SEC filings

KraneShares MSCI All China Health Care Index ETF

KURENYSE ArcaKraneSharesD

$17.34−0.28 (−1.59%)

At close: Nov 2, 2026, 4:00 PM ET

D26/ 100

Rank 23 of 25 in Health Care (Broad)

D26/100Rank 23 of 25inHealth Care (Broad)
Intraday session: down, 79 prints from 17.62 to 17.34. Range 17.34 to 17.66. Use the arrow keys to read each point.17.4017.4517.5017.5510 AM12 PM2 PM4 PM
Expense ratio
0.65%*
Fund size
$108M
1Y total return
−6.6%
Yield · Last 12 months
4.12%
Holdings
44
Avg volume · 30D
80.8K sh
52W range
low $14.38high $19.93
Launched
Filings
SEC EDGAR

*After a fee waiver that ends Aug 1, 2028. Without it: 0.79%.

The ETF.net KURE Grade

Based on 5 of 6 pillars

D

Score 26 out of 100

Category
Health Care (Broad)⁠
Rank
23 of 25
Six-pillar profile for KURE. Scores out of 100: Cost 27, Risk 9, Mission not scored, Tradability 24, Holdings 52, Durability 36. Strongest: Holdings (52). Weakest: Risk (9). Based on 5 of 6 pillars.

Score 26 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    D27 out of 100
    Rank 18 of 25

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    F9 out of 100
    Rank 24 of 25

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    F24 out of 100
    Rank 22 of 25

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    C52 out of 100
    Rank 16 of 25

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    D36 out of 100
    Rank 20 of 25

Our read on KURE

ETF.net Research

In short

DThe US-listed route into China's health care sector in one ticker: about 50 Chinese pharma and medical names listed in the Mainland, Hong Kong and the US. A narrow, volatile slice of a huge market, not a broad pharma fund.

Stated mandate

KURE is designed to track the MSCI China All Shares Healthcare 10/40 Index, which represents Chinese companies engaged in the healthcare sector.

Why people hold it

  • One ticker spans Chinese health care across all three venues it trades in: Mainland A-shares, Hong Kong and US listings. Most funds in this category stop at US pharma.kraneshares.com
  • Rules-based mandate, not a manager's China hunch: it tracks a published MSCI China health care benchmark and has been listed since 2018.sec.gov
  • About 50 holdings keeps it a pure China health care basket, with no US mega-cap pharma diluting the exposure.

Worth knowing

  • Costs 0.65% net of a waiver through August 1, 2028 (0.79% gross), above the health care category median. Broad US sector funds like XLV (0.08%) and VHT (0.09%) sit a tier below.
  • Single-country, single-sector, about 50 names: swings have run among the widest in its health care peer group, and Chinese policy shifts can move the whole basket.sec.gov
  • Moderately traded rather than a category heavyweight, so spreads and order type matter more. Distributions come once or twice a year, not monthly.

KURE Performance

Launched Jan 31, 2018

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.
KURE$9,338
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,146
Oct 31, 2025 to Nov 2, 2026. KURE $9,338. SPY $11,146. Use the arrow keys to read each point.$8,000$9,000$10,000$11,000Oct 2025May 2026Nov 2026

Oct 31, 2025 – Nov 2, 2026

Returns run to the Nov 2, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for KURE. Periods over one year show the average yearly return.
PeriodKURE
Year to date+1.8%
1 month−9.4%
3 months+0.3%
1 year−6.6%
3 yearsper year+0.1%
5 yearsper year−9.3%
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for KURE
YearReturn barKURE
2026 YTD+1.8%
2025+24.9%
2024−17.8%
2023−17.7%
2022−25.4%
2021−15.8%
2020+69.0%

KURE in the news

KURE Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Nov 2, 2026.
4.12%Last 12 months
Payout per share
$0.71Last 12 months
Last payment
$0.71 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2018–2026

One bar per payment. 8 payments from 2018 to 2026 YTD. Dec 26, 2018 $0.08; Dec 27, 2019 $0.06; Dec 29, 2020 $0.00011; Dec 29, 2021 $4.05; Dec 28, 2022 $0.01; Dec 18, 2023 $0.11; Dec 17, 2024 $0.18; Dec 22, 2025 $0.71. Use the arrow keys to read each point.201820192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Dec 22, 2025Dec 23, 2025$0.71
Dec 17, 2024Dec 18, 2024$0.18
Dec 18, 2023Dec 20, 2023$0.11
Dec 28, 2022Dec 30, 2022$0.01
Dec 29, 2021Dec 31, 2021$4.05
Dec 29, 2020Dec 31, 2020$0.00011
Dec 27, 2019Dec 31, 2019$0.06
Dec 26, 2018Dec 28, 2018$0.08

$10,000 in KURE 5 years ago paid $1,494 in dividends.

KURE Risk

Risk pillarF9 out of 100Rank 24 of 25 in Health Care (Broad)
How much the fund’s monthly returns vary, scaled to a year.
26.5%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
−0.02
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−58.6%
Trough Jul 2024
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.30
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

KURE Cost

Compare KURE and XLV

Overpaying vs XLV, cheapest in Health Care (Broad)

$11,028

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • KURE 0.65%

    $12,717

  • XLV 0.08% Cheapest

    $1,689

$10,000
30 years

Cost over time

  • KURE 0.65%
  • XLV 0.08%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K051015202530KURE $12,717XLV $1,689

Year by year

YearKUREXLVOverpaying
10$1,163$147$1,016
20$4,440$575$3,865
30$12,717$1,689$11,028
How the 0.65% is worked out

Full fee 0.79%− waiver 0.14%= you pay 0.65%

The waiver ends Aug 1, 2028. After that the fee is 0.79% unless KraneShares renews it. Source: prospectus, Jul 2026.

Other funds in Health Care (Broad)

See others